Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

Key facts

Study ID

NCT06947980

Run by

Keymed Biosciences Co.Ltd

People needed

200

Starts

2025-06-19

Expected to finish

2026-11-07

Last updated by the study team

2025-08-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a diagnosis of AD for at least 1 year according to the American Academy of Dermatology's consensus criteria prior to the screening visit meeting all of the following criteria:
• EASI≥16 at Screening and Baseline visits;
• Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits;
• 10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits;
• Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline;

You may not qualify if…

• Not enough washing-out period for previous therapy.
• Concurrent disease/status which may potentially affect the efficacy/safety judgement.
• Organ dysfunction.
• Pregnancy.
• Other.

Where it is running

• Peking University People's hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.